{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:32:25Z","timestamp":1793939545509,"version":"4.8.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) is an aggressive blood cancer with a 5-year overall survival rate of \u223c30%. Although immunotherapies engaging T cells demonstrate remarkable success in treating many solid tumors and blood cancers, they show little to no efficacy in treating AML. Therefore, immunotherapies are traditionally underappreciated and underdeveloped in AML. Through a drug repurposing screen, we identified and validated that combined MEK and HDAC inhibitions via trametinib and quisinostat (TQ) potently inhibited the growth of mouse and human NRAS\/ASXL1-driven (NA), MLL-rearranged, and NPM1-mutated AML cells in vitro. In NA-AML mice, TQ drastically slowed down AML progression and prolonged survival. The survival benefits of TQ largely relied on T-cell functions. We showed that TQ synergized to downregulate immune checkpoint ligands and upregulate the STAT1- and CIITA-mediated expression of major histocompatibility complex class I (MHC-I) and MHC-II in NA-AML cells. In addition, TQ treatment significantly reprogrammed the transcriptome and epigenetic landscape of T cells, activated STAT1 signaling, and upregulated genes and pathways promoting the activation, survival, and cytotoxicity of CD4 and CD8 T cells. A cytotoxic cluster was consequently expanded in central memory and effector memory T cells in TQ-treated NA-AML mice. More importantly, TQ directly acted on AML-associated mouse and human T cells, reverting them from a dysfunctional state to an active state. In leukemia:T-cell cocultures, TQ-treated T cells demonstrated greatly improved MHC-dependent killing of leukemia cells. Our findings suggest that the dual actions of TQ on NA-AML and T cells enhance leukemia recognition and antileukemia killing of endogenous T cells, leading to effective AML clearance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033417","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:00:04Z","timestamp":1785862804000},"page":"2384-2398","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Boosting antileukemia cytotoxicity of CD4 and CD8 T cells through combined inhibition of MEK and HDAC"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7434-7361","authenticated-orcid":false,"given":"Meher G.","family":"Bolisetti","sequence":"first","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Jia","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, Penn State Cancer Institute, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-1796","authenticated-orcid":false,"given":"Anthony","family":"Veltri","sequence":"additional","affiliation":[{"name":"3Bioinformatics Resource Core, University of Wisconsin Biotechnology Center, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vysakh","family":"Anandan","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8567-1644","authenticated-orcid":false,"given":"Maoshuo","family":"Yang","sequence":"additional","affiliation":[{"name":"4School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Chan","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1925-1306","authenticated-orcid":false,"given":"Sophie","family":"Verbeke","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangchen","family":"Yao","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Granozio","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Jiang","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra\u2019a","family":"Keewan","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2059-928X","authenticated-orcid":false,"given":"Jacqueline A.","family":"Cook","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Zhu","sequence":"additional","affiliation":[{"name":"4School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Ranheim","sequence":"additional","affiliation":[{"name":"5University of Wisconsin Carbone Cancer Center, Madison, WI"},{"name":"6Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[{"name":"7Division of Immunobiology, Cincinnati Children\u2019s Hospital, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsing","family":"Chou","sequence":"additional","affiliation":[{"name":"7Division of Immunobiology, Cincinnati Children\u2019s Hospital, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9625-1178","authenticated-orcid":false,"given":"Kalyan V. G.","family":"Nadiminti","sequence":"additional","affiliation":[{"name":"5University of Wisconsin Carbone Cancer Center, Madison, WI"},{"name":"8Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-6758","authenticated-orcid":false,"given":"H. Leighton","family":"Grimes","sequence":"additional","affiliation":[{"name":"7Division of Immunobiology, Cincinnati Children\u2019s Hospital, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Suresh","sequence":"additional","affiliation":[{"name":"9Department of Pathobiological Sciences, University of Wisconsin\u2013Madison, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Department of Medicine, Penn State Cancer Institute, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9996-1466","authenticated-orcid":false,"given":"Xiaona","family":"You","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"},{"name":"4School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1194-0666","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"1McArdle Laboratory for Cancer Research, University of Wisconsin\u2013Madison, Madison, WI"},{"name":"5University of Wisconsin Carbone Cancer Center, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2026110511220284200_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2026110511220284200_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026110511220284200_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-024-01054-2","article-title":"RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives","volume":"14","author":"Alawieh","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026110511220284200_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"issue":"7295","key":"2026110511220284200_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"issue":"11","key":"2026110511220284200_bib6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"2026110511220284200_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2012.288","article-title":"The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics","volume":"27","author":"Abdel-Wahab","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2026110511220284200_bib8","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41375-018-0083-3","article-title":"A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies","volume":"32","author":"Inoue","year":"2018","journal-title":"Leukemia"},{"issue":"23","key":"2026110511220284200_bib9","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2026110511220284200_bib10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1182\/blood.2021012519","article-title":"Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation","volume":"139","author":"You","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026110511220284200_bib11","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1038\/s41467-022-32692-4","article-title":"Covalent TCR-peptide-MHC interactions induce T cell activation and redirect T cell fate in the thymus","volume":"13","author":"Szeto","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2026110511220284200_bib12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2026110511220284200_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s002510050425","article-title":"Regulation of MHC class I and II gene transcription: differences and similarities","volume":"48","author":"van den Elsen","year":"1998","journal-title":"Immunogenetics"},{"issue":"10","key":"2026110511220284200_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nri1708","article-title":"Regulation of MHC class II gene expression by the class II transactivator","volume":"5","author":"Reith","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"2026110511220284200_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.molimm.2017.12.005","article-title":"The regulatory network behind MHC class I expression","volume":"113","author":"Jongsma","year":"2019","journal-title":"Mol Immunol"},{"issue":"9","key":"2026110511220284200_bib16","first-page":"2975","article-title":"Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNF-alpha in oligodendrocytes","volume":"10","author":"Agresti","year":"1998","journal-title":"Eur J Neurosci"},{"issue":"9","key":"2026110511220284200_bib17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1101\/gad.14.9.1156","article-title":"CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex","volume":"14","author":"Masternak","year":"2000","journal-title":"Genes Dev"},{"issue":"2","key":"2026110511220284200_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1074-7613(00)80468-9","article-title":"Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1","volume":"8","author":"Muhlethaler-Mottet","year":"1998","journal-title":"Immunity"},{"issue":"1","key":"2026110511220284200_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"2026110511220284200_bib20","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/cells12141882","article-title":"Insight into cancer immunity: MHCs, immune cells and commensal microbiota","volume":"12","author":"Wen","year":"2023","journal-title":"Cells"},{"issue":"5","key":"2026110511220284200_bib21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc1365","article-title":"Molecules and mechanisms of the graft-versus-leukaemia effect","volume":"4","author":"Bleakley","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2026110511220284200_bib22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2026110511220284200_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41571-020-0356-4","article-title":"Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD","volume":"17","author":"Blazar","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"49","key":"2026110511220284200_bib24","doi-asserted-by":"crossref","first-page":"e2116427118","DOI":"10.1073\/pnas.2116427118","article-title":"Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes","volume":"118","author":"Ferraro","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2026110511220284200_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","article-title":"Bispecific antibodies for the treatment of acute myeloid leukemia","volume":"13","author":"Guy","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"2026110511220284200_bib26","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.3390\/cancers15102713","article-title":"The black hole: CAR T cell therapy in AML","volume":"15","author":"Atilla","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026110511220284200_bib27","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","article-title":"The emerging role of immune checkpoint based approaches in AML and MDS","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2026110511220284200_bib28","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.hoc.2023.06.004","article-title":"Chimeric antigen receptor T cells in acute myeloid leukemia","volume":"37","author":"Cummins","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"issue":"23","key":"2026110511220284200_bib29","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1182\/bloodadvances.2025017011","article-title":"International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML","volume":"9","author":"Naik","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"2026110511220284200_bib30","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1097\/HS9.0000000000000350","article-title":"Beyond DNA damage: exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma","volume":"4","author":"Swan","year":"2020","journal-title":"Hemasphere"},{"issue":"14","key":"2026110511220284200_bib31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2018-05-852798","article-title":"CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice","volume":"132","author":"Fink","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026110511220284200_bib32","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3109\/10428194.2015.1117611","article-title":"Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma","volume":"57","author":"Moreau","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2026110511220284200_bib33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s001090050063","article-title":"Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways","volume":"74","author":"Whitmarsh","year":"1996","journal-title":"J Mol Med (Berl)"},{"issue":"7609","key":"2026110511220284200_bib34","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nature18600","article-title":"A combinatorial strategy for treating KRAS-mutant lung cancer","volume":"534","author":"Manchado","year":"2016","journal-title":"Nature"},{"issue":"22","key":"2026110511220284200_bib35","doi-asserted-by":"crossref","first-page":"8489","DOI":"10.1128\/MCB.20.22.8489-8498.2000","article-title":"Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes","volume":"20","author":"Spilianakis","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"12","key":"2026110511220284200_bib36","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","article-title":"Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox","volume":"54","author":"Oh","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"2026110511220284200_bib37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s42003-024-06563-1","article-title":"Oligoclonal CD4+ CXCR5+ T cells with a cytotoxic phenotype appear in tonsils and blood","volume":"7","author":"Liang","year":"2024","journal-title":"Commun Biol"},{"issue":"1","key":"2026110511220284200_bib38","doi-asserted-by":"crossref","first-page":"14954","DOI":"10.1038\/s41598-022-19256-8","article-title":"ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control","volume":"12","author":"Blair","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"2026110511220284200_bib39","doi-asserted-by":"crossref","first-page":"108545","DOI":"10.1016\/j.celrep.2020.108545","article-title":"CDK8 fine-tunes IL-6 transcriptional activities by limiting STAT3 resident time at the gene loci","volume":"33","author":"Martinez-Fabregas","year":"2020","journal-title":"Cell Rep"},{"issue":"4","key":"2026110511220284200_bib40","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/2326-6066.CIR-17-0183","article-title":"NK cell-specific CDK8 deletion enhances antitumor responses","volume":"6","author":"Witalisz-Siepracka","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"2026110511220284200_bib41","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1038\/s41375-021-01198-1","article-title":"EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia","volume":"35","author":"Llao-Cid","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2026110511220284200_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5114\/ceji.2014.42135","article-title":"Perforin: an important player in immune response","volume":"39","author":"Osinska","year":"2014","journal-title":"Cent Eur J Immunol"},{"issue":"2","key":"2026110511220284200_bib43","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/2326-6066.CIR-21-0539","article-title":"NKG7 is a T-cell-intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy","volume":"10","author":"Wen","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2026110511220284200_bib44","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/cancers13061263","article-title":"Harnessing the IL-21-BATF pathway in the CD8+ T cell anti-tumor response","volume":"13","author":"Topchyan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026110511220284200_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imm.12136","article-title":"Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma","volume":"140","author":"Cycon","year":"2013","journal-title":"Immunology"},{"issue":"6","key":"2026110511220284200_bib46","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3390\/vaccines13060550","article-title":"Synergistic integration of HDAC inhibitors and individualized neoantigen therapy (INT): a next-generation combinatorial approach for cancer immunotherapy","volume":"13","author":"Han","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"2026110511220284200_bib47","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.4049\/jimmunol.2000612","article-title":"Dynamic roles for IL-2-STAT5 signaling in effector and regulatory CD4+ T cell populations","volume":"205","author":"Jones","year":"2020","journal-title":"J Immunol"},{"issue":"3","key":"2026110511220284200_bib48","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","article-title":"Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer","volume":"57","author":"Shouse","year":"2024","journal-title":"Immunity"},{"issue":"13","key":"2026110511220284200_bib49","doi-asserted-by":"crossref","first-page":"e18470","DOI":"10.1111\/jcmm.18470","article-title":"Immune-related adverse events of antibody-based biological medicines in cancer therapy","volume":"28","author":"Rajagopal","year":"2024","journal-title":"J Cell Mol Med"},{"issue":"4","key":"2026110511220284200_bib50","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41375-019-0645-z","article-title":"Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents","volume":"34","author":"Kubasch","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2026110511220284200_bib51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026110511220284200_bib52","doi-asserted-by":"crossref","first-page":"200773","DOI":"10.1016\/j.omton.2024.200773","article-title":"Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party","volume":"32","author":"Lu","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"10","key":"2026110511220284200_bib53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/19\/2384\/2597988\/blood_bld-2026-033417-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/19\/2384\/2597988\/blood_bld-2026-033417-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:22:13Z","timestamp":1793895733000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/19\/2384\/570010\/Boosting-antileukemia-cytotoxicity-of-CD4-and-CD8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,5]]},"references-count":53,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,11,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033417","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,5]]},"published":{"date-parts":[[2026,11,5]]}}}